Veliparib-carboplatin combo is first 'graduate' of I-SPY2 trial

In contrast, the difference in estimated pCR rates with addition of veliparib-carboplatin was much smaller among all patients with HER2-negative disease (33% vs. 22%) and in the opposite direction among the subset with hormone receptor–positive, HER2-negative disease (14% vs. 19%). The predictive probabilities that the combination with chemotherapy would be superior in phase 3 testing in these groups were just 55% and 9%, respectively.

"The toxicity was moderately increased as expected, but it was well managed with dose reduction and delay," Dr. Rugo reported.

Dr. Rugo disclosed no relevant conflicts of interest.